Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,529 total articles
Modine's shares have pulled back from the froth of the spring rally. That weakness is a buying opportunity. A large hyperscaler contract, accelerating data-center cooling demand driven by AI, and a planned spinoff of lower-margin operations support re-rating. Valuation is rich today, but the revenue and cash-flow lift expected in 2027–2029 justify …
Stryker ($SYK) reported a disrupted quarter that sent the stock down from its 52-week highs. The fundamentals - $125B market cap, $4.57B free cash flow, 14.5% ROE - argue for patience. This trade buys the dip with a clear entry, stop and $375 target, expecting normalization in procedure volumes, benefits from the Amplitude Vascular acquisition, and…
Yellow Cake is a play on physical uranium exposure with a newly credible catalyst - a share buyback program - that should compress the long-standing discount to NAV and create a clear path for upside. This trade plan lays out an entry at $5.20, stop at $3.90 and target at $8.50 with a primary horizon of 180 trading days.
T-Mobile is trading at roughly $179 and offers a compelling risk-reward: strong free cash flow ($18.2B), mid-teens ROE, and an EV/EBITDA of 8.7. Those fundamentals, combined with durable postpaid economics and a 2.2% yield, argue for a multiple expansion trade toward $224 over the next several months. Manageable leverage and a clear stop beneath th…
<p>Micron is at the center of an intensifying memory cycle driven by AI data-center demand and constrained supply. The company’s expansion plan and strong cash flow profile give it real leverage as high-bandwidth memory (HBM) and DRAM tightness push pricing power higher. This trade idea outlines a mid-term long entry at near-term prices with a defi…
Nomura's pivot toward global asset management and steady wholesale performance, combined with a modest valuation (market cap ~$29.7B, P/E ~12), supports a long trade. Entry at $9.54, stop at $8.50 and a $11.50 target over a long-term horizon (180 trading days) captures integration upside, fee growth and potential multiple expansion while acknowledg…
Novo Nordisk’s move to an oral Wegovy offering ramps competitive pressure on Eli Lilly but also crystallizes the company’s multi-channel defense. At current levels near $48.90, the stock looks like a mid-term buy: attractive valuation for a market-cap leader ($220.3B), supportive technicals and rising short interest give upside with defined risk. T…
Planet Labs launched Pelican-11, a step that could improve imagery cadence and product stickiness. The stock trades at a premium – market cap near $9.9B and price-to-sales of about 29.5x – but positive free cash flow, improving technicals, and a concentrated short base make a tactical long attractive. This trade plan lays out entry, target, and sto…
POWI is a high-quality analog semiconductor exposed to industrial, automotive and consumer power conversion markets. The core thesis is a recovery in industrial power spending and margin tailwinds from restructuring; Nvidia-related design wins are a high-impact optionality, not the base case. Valuation is rich today, so this trade uses a defined en…
Moelis & Company (MC) trades near $64.63 after a sharp two-session selloff. The firm combines high return on equity, robust free cash flow and zero debt with a meaningful dividend yield, creating a case for a defined-risk long trade. Entry at $64.63 with a $60 stop and a $78.22 target offers asymmetric upside while limiting capital at risk.
DocuSign is trading like a growth liability rather than a profitable SaaS with attractive cash flow. With market cap near $9.0B, positive free cash flow of ~$1.12B, improving profitability and an AI-driven Intelligent Agreement Management (IAM) business already at ~12.6% of ARR, the current setup favors a tactical long. We upgrade to BUY for a mid-…
Magellan Aerospace has the structural setup investors should like: steady defense contracts, improving commercial OEM demand, and a manufacturing footprint that benefits program wins and aftermarket growth. This trade idea lays out an entry at $8.50, a $13.00 target and a $6.50 stop for a long-term push over the next 180 trading days.
Novo Nordisk looks oversold relative to its market position. At roughly $220.3B market cap, a 11.6x P/E and 2.48% yield create a compelling risk-reward for a long trade while the company consolidates after a sharp multi-month pullback.
Bank of America passed the Fed stress tests, trades at a reasonable multiple with a $413.8B market cap, and has technical momentum. A convertible-preferred-style exposure (or owning the common as a proxy) captures yield today and upside if common equity rerates. Trade plan provided with entry, stop and target for a long-duration trade.
Best Buy reported a better-than-expected Q1 with revenue of $8.94B, comparable sales +2%, and margin expansion. At $78, the stock offers a near-5% yield and reasonable valuation metrics (P/E ~14.4, EV/EBITDA ~6.1), making a short-to-mid-term income trade attractive. Upside to the prior highs is limited, so this is a yield-first, risk-managed long r…
Argan (AGX) is benefiting from the AI-driven surge in power and data-center construction. With a $2.9B backlog, 50% revenue growth year-over-year and strong free cash flow, the company has the fundamentals to support further gains. That said, lofty multiples and a short-term technical pullback argue for an entry with a tight stop and a clearly defi…
Strategic Education (STRA) is transitioning from a largely consumer-facing higher-education company toward recurring B2B revenue via employer-sponsored education programs. Valuation is reasonable (P/E ~14.4, EV/EBITDA 7), free cash flow is healthy ($173.9M), and technicals are constructive. I view STRA as a buy with an explicit entry, stop and targ…
Palantir remains a unique hybrid: a defense-funded cash generator with an emerging AI orchestration product that could re-rate the stock. Valuation is stretched today, but a disciplined swing-long with a clear stop can capture upside if commercial AI adoption accelerates.
Kailera Therapeutics is a newly public, clinical-stage biotech built around ribupatide — a GLP-1/GIP dual agonist being developed as both an oral pill and a weekly injection. Phase 2 signals (mean weight loss up to 12.1%; 38.6% achieving 15% at 26 weeks) plus $718.8M in IPO proceeds give the company multiple shots at commercialization. At a $2.82B …
Vonovia (VONOY) is trading at a steep discount to book value with a 5.5% yield and a low PE. Technicals show steady footing and the balance sheet scale gives optionality. We recommend buying for a mid-term rebound to $17 while carrying a disciplined stop.
SAP is mid-way through a multi-year transformation from license-heavy ERP to cloud-first subscription software and AI-enabled services. With a market cap near $195.5B, a reasonable PE of 21.9 and improving technicals, the risk-reward favors a long trade around $157.79. The trade banks on accelerating S/4HANA migrations, stronger cloud margins over …
<p>Genpact (G) trades at roughly $29.34 today and looks materially undervalued versus its fundamentals. The business generates strong free cash flow ($668.7M), posts healthy returns on equity (23%) and assets (10%), and carries a reasonable leverage profile (debt/equity ~0.62). At a market cap near $4.97B the stock sits at ~8.7x reported EPS and an…
DraftKings looks poised to trade higher as 2026 catalysts - the FIFA World Cup, the upcoming NFL season, and regulatory moves favoring licensed sportsbooks - converge. The stock recently basing near its 52-week low while technicals show improving momentum. This trade idea proposes a tactical long with clearly defined entry, stop, and target levels …
Texas Pacific Land (TPL) owns premium surface and royalty positions in the Permian Basin and has positioned itself as a landlord to both energy and emerging AI infrastructure. The balance sheet, recurring fee businesses (easements, water, materials) and growing data-center related opportunities justify a directional long. This trade idea lays out a…
Cerebras is positioned to monetize wafer-scale AI acceleration across hyperscalers and enterprise clouds. With growing commercial traction at hyperscalers and early cloud integrations that reduce buyer friction, the stock offers asymmetric upside. This trade sets a clear entry at $25, a $50 upside target, and an $18 stop, sized for a long-term (180…
